An Open-label, Rollover Study Providing Continued Dosing... | NCT02258854

Official Title

An Open-Label, Non-Randomized, Single-Arm, Rollover Study to Continue Dosing of Gevokizumab in Subjects With Non Infectious Intermediate-, Posterior-, or Pan-Uveitis Patients Who Each Successfully Completed Either the X052130/CL3-78989-005 (EYEGUARD™-A) or the X052131/CL3-78989-006 (EYEGUARD™-C) Study or Who Have Controlled Ocular Inflammation After Receiving Study Drug in Study X052133 (EYEGUARD™-US)

Status Module

Oversight Module

Description Module

Design Module

Interventional Study Design

Biospecimen

No data available

No data is available for this block.

Arms/Interventions Module

Label	Type	Description	Intervention Names
Dose 2 gevokizumab	Experimental		Drug: Dose 2 gevokizumab

Name	Type	Description	Arm Group Labels	Other Names
Dose 2 gevokizumab	Drug	Solution for subcutaneous injection	Dose 2 gevokizumab

Measure	Description	Time Frame
Treatment-emergent Adverse Events		108 weeks

Eligibility Module

Derived Section

Miscellaneous Info Module

Submission Tracking

No data available

No data is available for this block.

Condition Browse Module

Intervention Browse Module

No data available

No data is available for this block.

Facility	Status	City	State	ZIP	Country	Contacts
		Chandler	Arizona		United States

ID	Term
D014605	Uveitis
D015867	Uveitis, Intermediate
D015866	Uveitis, Posterior
D015864	Panuveitis

ID	Term
D014603	Uveal Diseases
D005128	Eye Diseases